Assessment of Thermal Stability of Mutant p53 Proteins via Differential Scanning Fluorimetry

The p53 protein is a transcription factor that preserves the integrity of the genome. The TP53 gene has inactivating mutations in about 50% of all human cancers. Some missense mutations lead to decreased thermal stability in the p53 protein, its unfolding and aggregation under physiological conditions. A general understanding of the impact of point mutations on the stability and conformation of mutant p53 is essential for the design and development of small molecules that target specific p53 mutations. In this work, we determined the thermostability properties of some of the most common mutant forms of the p53 protein—p53(R273H), p53(R248Q), p53(R248W) and p53(Y220C)—that are often considered as attractive therapeutic targets. The results showed that these missense mutations lead to destabilization of the p53 protein and a decrease in its melting temperature.

[1]  A. Joerger,et al.  Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220C , 2022, ACS pharmacology & translational science.

[2]  M. Oren,et al.  Drugging p53 in cancer: one protein, many targets , 2022, Nature Reviews Drug Discovery.

[3]  Guanghong Wei,et al.  Unraveling the Allosteric Mechanism of Four Cancer-related Mutations in the Disruption of p53-DNA Interaction. , 2021, The journal of physical chemistry. B.

[4]  Johnson Wahengbam Luwang,et al.  Stability of p53 oligomers: Tetramerization of p53 impinges on its stability. , 2021, Biochimie.

[5]  Jiale Wu,et al.  Three optimized assays for the evaluation of compounds that can rescue p53 mutants , 2021, STAR protocols.

[6]  Ying Liang,et al.  Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site. , 2020, Cancer cell.

[7]  A. Kamburov,et al.  Identification of Small Molecules that Modulate Mutant p53 Condensation , 2020, iScience.

[8]  A. Rizvanov,et al.  Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy , 2020, Frontiers in Oncology.

[9]  R. Samudrala,et al.  Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function , 2020, Nature Communications.

[10]  A. Fersht,et al.  Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm , 2020, ACS chemical biology.

[11]  A. Fersht,et al.  A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C , 2019, Future medicinal chemistry.

[12]  A. Garg,et al.  Variable Mutations at the p53-R273 Oncogenic Hotspot Position Leads to Altered Properties , 2019, bioRxiv.

[13]  T. Massoud,et al.  Restoring guardianship of the genome: Anticancer drug strategies to reverse oncogenic mutant p53 misfolding. , 2018, Cancer treatment reviews.

[14]  K. Wiman,et al.  Targeting mutant p53 for efficient cancer therapy , 2017, Nature Reviews Cancer.

[15]  K. Wiman,et al.  APR-246 reactivates mutant p53 by targeting cysteines 124 and 277 , 2017, Cell Death & Disease.

[16]  Dmitriy Sonkin,et al.  TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data , 2016, Human mutation.

[17]  A. Fersht,et al.  The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches. , 2016, Annual review of biochemistry.

[18]  T. Soussi,et al.  TP53: an oncogene in disguise , 2015, Cell Death and Differentiation.

[19]  Jennifer A. Littlechild,et al.  Determination of Protein-ligand Interactions Using Differential Scanning Fluorimetry , 2014, Journal of visualized experiments : JoVE.

[20]  A. Fersht,et al.  Abstract 2472: Small-molecule-induced reactivation of mutant p53 in cancer cells. , 2013 .

[21]  Rainer Wilcken,et al.  Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition , 2012, Proceedings of the National Academy of Sciences.

[22]  K. Wiman,et al.  Pharmacological reactivation of mutant p53: from protein structure to the cancer patient , 2010, Oncogene.

[23]  A. Fersht,et al.  The tumor suppressor p53: from structures to drug discovery. , 2010, Cold Spring Harbor perspectives in biology.

[24]  A. Fersht,et al.  Structural biology of the tumor suppressor p53. , 2008, Annual review of biochemistry.

[25]  F. Niesen,et al.  The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.

[26]  Sebastian Mayer,et al.  Effects of Common Cancer Mutations on Stability and DNA Binding of Full-length p53 Compared with Isolated Core Domains* , 2006, Journal of Biological Chemistry.

[27]  A. Fersht,et al.  Structures of p53 Cancer Mutants and Mechanism of Rescue by Second-site Suppressor Mutations* , 2005, Journal of Biological Chemistry.

[28]  A. Fersht,et al.  Kinetic Instability of p53 Core Domain Mutants , 2003, Journal of Biological Chemistry.

[29]  A. Fersht,et al.  Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy , 2000, Oncogene.

[30]  A. Fersht,et al.  Thermodynamic stability of wild-type and mutant p53 core domain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[32]  B. Janssen,et al.  The Use of Differential Scanning Fluorimetry to Assess Strigolactone Receptor Function. , 2021, Methods in molecular biology.

[33]  A. Fersht,et al.  Structural biology of the tumor suppressor p53 and cancer-associated mutants. , 2007, Advances in cancer research.